Medicare AdvantageCoverageLow impact
MA08.019p, Intravenous Infliximab and Related Biosimilars
Independence Blue Cross·MA · Rheumatology, Gastroenterology, Dermatology +1 more·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.019p for Intravenous Infliximab and Related Biosimilars was posted on 11/17/2025 and immediately removed on the same date. This policy is no longer active. The billing team should disregard this policy and continue following previously established guidance for infliximab infusions and biosimilar coverage.
Action Required
No action required. Policy MA08.019p was removed on 11/17/2025 and is not currently in effect. Billing team should verify current infliximab coverage and prior authorization requirements by consulting the active policy documentation or contacting the plan directly. Do not implement any billing or authorization changes based on this removed policy.